Patrick S. Ward, Ph.D.
Affiliations: | 2013 | Cell and Molecular Biology | University of Pennsylvania, Philadelphia, PA, United States |
Google:
"Patrick Ward"Mean distance: 25144.9
Parents
Sign in to add mentor| Garret A. FitzGerald | grad student | 2013 | Penn | |
| (The common feature of cancer-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to the oncometabolite 2-hydroxyglutarate.) | ||||
| Vamsi Mootha | post-doc | Harvard (Cell Biology Tree) | ||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Peterson AA, Rangwala AM, Thakur MK, et al. (2022) Discovery and molecular basis of subtype-selective cyclophilin inhibitors. Nature Chemical Biology |
| Rath S, Sharma R, Gupta R, et al. (2020) MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Research |
| Lu C, Venneti S, Akalin A, et al. (2013) Induction of sarcomas by mutant IDH2. Genes & Development. 27: 1986-98 |
| Ward PS, Lu C, Cross JR, et al. (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. The Journal of Biological Chemistry. 288: 3804-15 |
| Turcan S, Rohle D, Goenka A, et al. (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483: 479-83 |
| Wise DR, Ward PS, Shay JE, et al. (2011) Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proceedings of the National Academy of Sciences of the United States of America. 108: 19611-6 |